4.6 Article

Measurement properties of the Patient-Reported Outcomes Information System (PROMIS(R)) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis

Journal

BRITISH JOURNAL OF DERMATOLOGY
Volume 183, Issue 5, Pages 891-898

Publisher

OXFORD UNIV PRESS
DOI: 10.1111/bjd.18978

Keywords

-

Categories

Funding

  1. Agency for Healthcare Research and Quality (AHRQ) [K12 HS023011]
  2. Dermatology Foundation
  3. Galderma

Ask authors/readers for more resources

Background Little is known about the validity of numeric rating scales (NRS) and verbal rating scales (VRS) for itch and itch frequency for assessing itch severity in atopic dermatitis (AD). We evaluated the Patient-Reported Outcomes Information System (PROMIS(R)) Itch Questionnaire (PIQ) - itch severity assessment, including multiple NRS, VRS and frequency of itch assessments, in adults with AD and compared their performance. Methods Self-administered questionnaires and skin examinations were performed in 410 patients with AD (aged 18-90 years) in a dermatology practice setting. Results PIQ NRS, VRS and frequency of itch had good content validity, strong correlations with one another (Spearman correlations P < 0 center dot 001) and weak-to-moderate correlations with patient-oriented eczema measure (POEM), Eczema Area and Severity Index (EASI), objective SCORing AD (SCORAD) and Dermatology Life Quality Index (DLQI) (P < 0 center dot 001) and very good discriminant validity. Changes from baseline in NRS, VRS and frequency of itch were moderately to strongly correlated with one another, and weakly to moderately correlated with other patient-reported (POEM, SCORAD itch, DLQI) and clinician-reported outcomes (EASI, objective SCORAD). NRS and VRS worst itch and average itch showed moderate-to-good test-retest reliability. There were no floor or ceiling effects for NRS or VRS itch, but there were ceiling effects for itch frequency. Each assessment was completed in < 1 min by all patients. Conclusions NRS, VRS and frequency of itch items from PIQ - itch severity showed good content and construct validity, reliability, and/or responsiveness in adults with AD, and were feasible for use in clinical trials and practice. What is already known about this topic? Numeric rating scales (NRS), verbal rating scales (VRS) and frequency of itch have been used to assess the burden of itch. However, there have been limited results demonstrating their validity, responsiveness, interpretability and feasibility, particularly in atopic dermatitis (AD). What does this study add? This study demonstrated that NRS, VRS and frequency of itch items from the Patient-Reported Outcomes Information System (PROMIS(R)) Itch Questionnaire (PIQ) - itch severity assessments had good construct validity, responsiveness, reliability and feasibility in the assessment of adult AD. PIQ NRS, VRS and frequency of itch all appear to have sufficient validity, reliability and feasibility for use as assessments of itch in adults with AD in clinical practice and trials. What are the clinical implications of this work? PIQ NRS and VRS are all simple, valid, reliable and feasible for use in clinical practice and trials to assess itch in adults with AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Dermatology

Anesthetization of the tragus and antitragus to use skin hooks for full visualization of the auricular concha

Brett C. Neill, Vivek Singam, Isadore S. Tarantino, Lindsey B. Bauer, Thomas L. H. Hocker

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2023)

Letter Dermatology

Single-question parent-reported global atopic dermatitis severity: A valid instrument in children

Jonathan I. Silverberg, Stephanie M. Rangel, Anjani Sheth, Alli Blumstein, Amy S. Paller

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2023)

Editorial Material Allergy

Co-reactivity of glucosides: Retrospective analysis of North American Contact Dermatitis Group Data 2019-2020

Erin M. Warshaw, Michelle Xiong, Joel G. DeKoven, James S. Taylor, Donald V. Belsito, Margo J. Reeder, Brandon L. Adler, Melanie D. Pratt, Amber R. Atwater, Howard I. Maibach, Jonathan I. Silverberg, JiaDe Yu, Nina Botto, Joseph F. Fowler, Marie-Claude Houle, Christen M. Mowad, Cory A. Dunnick, Vincent A. DeLeo

CONTACT DERMATITIS (2023)

Article Dermatology

Prevalence, Predictors, and Longitudinal Course of Sexual Dysfunction in Adults With Atopic Dermatitis

Trisha Kaundinya, Uros Rakita, Jonathan I. Silverberg

Summary: This study examined the prevalence and associations of sexual dysfunction (SD) in adults with atopic dermatitis (AD). The results showed that 19.35% of patients reported SD, which was associated with marital status, age, and severity of AD.

DERMATITIS (2023)

Review Allergy

Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms

Juan Jose Yepes-Nunez, Gordon H. Guyatt, Luis Guillermo Gomez-Escobar, Lucia C. Perez-Herrera, Alexandro W. L. Chu, Renata Ceccaci, Ana Sofia Acosta-Madiedo, Aaron Wen, Sergio Moreno-Lopez, Margaret MacDonald, Monica Barrios, Xiajing Chu, Nazmul Islam, Ya Gao, Melanie M. Wong, Rachel Couban, Elizabeth Garcia, Edgardo Chapman, Paul Oykhman, Lina Chen, Tonya Winders, Rachel Netahe Asiniwasis, Mark Boguniewicz, Anna De Benedetto, Kathy Ellison, Winfred T. Frazier, Matthew Greenhawt, Joey Huynh, Elaine Kim, Jennifer LeBovidge, Mary Laura Lind, Peter Lio, Stephen A. Martin, Monica O'Brien, Peck Y. Ong, Jonathan I. Silverberg, Jonathan Spergel, Julie Wang, Kathryn E. Wheeler, Lynda Schneider, Derek K. Chu

Summary: This article summarizes the evidence regarding the benefits and harms of allergen immunotherapy (AIT) for atopic dermatitis (AD). The findings indicate that subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) can significantly improve the severity and quality of life of AD patients, but they may also increase adverse events. Therefore, a multidisciplinary and shared decision-making approach should be adopted for optimal management of AD.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2023)

Article Allergy

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies

Emma Guttman-Yassky, Jacob P. Thyssen, Jonathan I. Silverberg, Kim A. Papp, Amy S. Paller, Stephan Weidinger, H. Chih-ho Hong, Barbara Hendrickson, Deanne Dilley, Allan R. Tenorio, Barry Ladizinski, Alvina D. Chu, John Liu, Alan D. Irvine

Summary: This study evaluated the safety of upadacitinib in patients with moderate-to-severe atopic dermatitis. The results showed that upadacitinib was well tolerated by both adults and adolescents. The frequency of adverse events was higher in the 30 mg group compared to the 15 mg group, but the rates of serious adverse events were similar in both groups. Acne was the most commonly reported adverse event.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2023)

Article Dermatology

Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7

Jonathan I. Silverberg, Eric L. Simpson, Jacob Pontoppidan Thyssen, Thomas Werfel, Tracy E. Cardillo, Stephanie Colvin, Evangeline Pierce, Yun-Fei Chen, Sherry Chen, Lawrence Eichenfield

Summary: Baricitinib combined with topical corticosteroids (TCS) has shown sustained efficacy in treating adults with moderate-to-severe atopic dermatitis (AD) over a 68-week period.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)

Jonathan I. Silverberg, Robert Bissonnette, Leon Kircik, Dedee F. Murrell, Andrew Selfridge, Kris Liu, Gurpreet Ahluwalia, Emma Guttman-Yassky

Summary: This study evaluated the efficacy and safety of etrasimod monotherapy in the treatment of moderate-to-severe atopic dermatitis. The results showed that etrasimod 2 mg demonstrated efficacy on clinician- and patient-assessed measures, and both 1 mg and 2 mg doses were well tolerated, supporting further clinical investigation in atopic dermatitis.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

Prevalence and associations of fatigue in childhood atopic dermatitis: A cross-sectional study

Stephanie M. Rangel, Theodore Kim, Anjani Sheth, Alli Blumstein, Jin-Shei Lai, David Cella, Amy S. Paller, Jonathan Silverberg

Summary: This study aims to determine the prevalence of fatigue in AD patients, and whether AD severity, demographics and comorbidities are associated with increased fatigue in children. The results showed that many children with AD had no or mild fatigue, but fatigue was associated with AD severity, history of allergic diseases, and family income.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Review Dermatology

Values and Preferences of Patients and Caregivers Regarding Treatment of Atopic Dermatitis (Eczema) A Systematic Review

Keon Andre Maleki-Yazdi, Anja Fog Heen, Irene X. Zhao, Gordon H. Guyatt, Erica A. Suzumura, Nima Makhdami, Lina Chen, Tonya Winders, Kathryn E. Wheeler, Julie Wang, Jonathan Spergel, Jonathan I. Silverberg, Peck Y. Ong, Monica O'Brien, Stephen A. Martin, Peter A. Lio, Mary Laura Lind, Jennifer LeBovidge, Elaine Kim, Joey Huynh, Matthew Greenhawt, Winfred T. Frazier, Kathy Ellison, Korey Capozza, Anna De Benedetto, Mark Boguniewicz, Wendy Smith Begolka, Rachel Netahe Asiniwasis, Lynda C. Schneider, Derek K. Chu

Summary: This article systematically summarizes patient values and preferences in the management of atopic dermatitis (AD). Six key themes have been identified that may inform optimal clinical care, practice guidelines, and future research.

JAMA DERMATOLOGY (2023)

Article Dermatology

Trends in the Prevalence of Methylchloroisothiazolinone/Methylisothiazolinone Contact Allergy in North America and Europe

Margo J. Reeder, Erin Warshaw, Srikanth Aravamuthan, Donald V. Belsito, Johannes Geier, Mark Wilkinson, Amber Reck Atwater, Ian R. White, Jonathan I. Silverberg, James S. Taylor, Joseph F. Fowler Jr, Howard I. Maibach, Joel G. DeKoven, Timo Buhl, Nina Botto, Ana Maria Gimenez-Arnau, Rosella Gallo, Christen Mowad, Claudia C. V. Lang, Vincent A. DeLeo, Graham Johnston, Melanie D. Pratt, Knut Brockow, Brandon L. Adler, Marie-Claude Houle, Heinrich Dickel, Marie Louise A. Schuttelaar, JiaDe Yu, Radoslaw Spiewak, Cory Dunnick, Francesca Larese Filon, Skaidra Valiukeviciene, Wolfgang Uter

Summary: From 2017 to 2018, the number of cases of isothiazolinone allergy decreased in Europe while it continued to increase in North America. This may be attributed to earlier and more stringent government regulation of isothiazolinones in Europe.

JAMA DERMATOLOGY (2023)

Article Dermatology

Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis A Post Hoc Analysis of 6 Randomized Clinical Trials

Amy S. Paller, Jonathan I. Silverberg, Michael J. Cork, Emma Guttman-Yassky, Benjamin Lockshin, Alan D. Irvine, Moon Bum Kim, Kenji Kabashima, Zhen Chen, Yufang Lu, Ashish Bansal, Ana B. Rossi, Arsalan Shabbir

Summary: This study assessed the efficacy and safety of dupilumab in patients with severe erythrodermic atopic dermatitis (AD). The results showed that dupilumab significantly improved AD signs and symptoms, including affected body surface area, Eczema Area and Severity Index (EASI) score, and Pruritus Numerical Rating Scale (PP-NRS) score. The treatment also led to reductions in serum biomarker levels.

JAMA DERMATOLOGY (2023)

Article Dermatology

Efficacy and Safety of Dupilumab Maintained in Adults=60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials

Jonathan I. Silverberg, Charles W. Lynde, Katrina Abuabara, Cataldo Patruno, Anna de Benedetto, Haixin Zhang, Ryan B. Thomas, Gaelle Bego-Le-Bagousse, Faisal A. Khokhar, Jignesh Vakil, Ainara Rodriguez Marco, Noah A. Levit

Summary: This study reported the efficacy and safety of dupilumab in patients aged ≥ 60 years with moderate-to-severe atopic dermatitis. The results showed significant improvements in skin lesions, symptoms, biomarkers, and quality of life in dupilumab-treated patients at week 16. The safety profile of dupilumab in patients aged ≥ 60 years was consistent with previous findings.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2023)

Article Dermatology

Racial disparities in dermatology

Shanthi Narla, Candrice R. Heath, Andrew Alexis, Jonathan I. Silverberg

Summary: Significant racial/ethnic disparities in dermatologic care and their subsequent impact on dermatologic conditions were reported. Key contributing factors include socioeconomic factors, gaps in educational exposure, and underrepresentation of minority groups in the dermatologic workforce. The American Academy of Dermatology (AAD) announced a three-year plan to promote diversity, equity, and inclusion in dermatology. To reduce disparities, every dermatologist should receive adequate education in diseases, treatments, health equity, and culturally sensitive care. A diverse dermatologic workforce can improve cross-cultural understanding and treatment approaches for different racial/ethnic populations, while acknowledging and educating on the health impacts of racism is essential for the healthcare community.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2023)

Review Dermatology

Association of autoimmune blistering disease, and specifically, pemphigus vulgaris, with cardiovascular disease and its risk factors: a systematic review and meta-analysis

Alex M. Rokni, Marissa Ayasse, Adnan Ahmed, Lauren Guggina, Robert W. Kantor, Jonathan Silverberg

Summary: This study systematically reviewed the relationship between autoimmune blistering disease (AIBD) and cardiovascular disease (CVD) and its risk factors. The findings showed that AIBD was associated with diabetes, hypertension, dyslipidemia, and heart failure, but not with obesity, stroke, angina, heart attack, or arrhythmia. The study also found that treatment for AIBD could result in CVD-related adverse events.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2023)

No Data Available